Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Sandra Lord, Carla J Greenbaum

Abstract

With more than four decades of clinical research and 25 years of clinical trials, much is known about the natural history of T1D before and after clinical diagnosis. We know that autoimmunity occurs early in life, that islet autoimmunity inevitably leads to clinically overt disease, and that some immune therapies can alter the disease course. In the future, we will likely conduct trials to more deeply explore mechanisms of disease and response to therapy, employ combinations of agents including those aimed at supporting beta cells, consider the use of chronic, intermittent therapy, focus studies on preventing progression from islet autoimmunity, and consider the potential benefits of studying children independently from adults. Much of this work will depend upon clinical trial networks such as Diabetes TrialNet. Such networks not only have the expertise to conduct studies but their sharing of data and samples also allows for discovery work by multiple investigators, laying the groundwork for the future. Working with patients, families, funders and industry, such collaborative networks can accelerate the translation of science to clinical practice to improve the lives of those living with T1D.

References

Mar 2, 1989·The New England Journal of Medicine·S C ShahN E Simpson
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·L ChatenoudJ F Bach
May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Oct 4, 2002·The New England Journal of Medicine·Joep Killestein
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Mar 14, 2007·Clinical and Experimental Immunology·T Staeva-VieiraM von Herrath
Oct 1, 2008·Pediatric Diabetes·Jeffrey L MahonUNKNOWN Type 1 Diabetes TrialNet Study Group
Jan 6, 2009·Annals of the New York Academy of Sciences·Jay S Skyler, UNKNOWN Type 1 Diabetes TrialNet Study Group
Jun 9, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Mark A Atkinson, Roberto Gianani
Jan 14, 2010·Diabetes Care·Peter A GottliebUNKNOWN Type 1 Diabetes TrialNet MMF/DZB Study Group
Jun 5, 2010·Pediatric Diabetes·Carla J GreenbaumBarbara Brooks-Worrell
Feb 23, 2012·Diabetes Care·Carla J Greenbaum
Jun 23, 2012·Diabetes·S Alice LongUNKNOWN Diabetes TrialNet and the Immune Tolerance Network
Jun 23, 2012·Diabetes Care·Franca B BartonA M James Shapiro
Mar 27, 2013·Diabetes Research and Clinical Practice·Johnny LudvigssonUlf Samuelsson
Jun 20, 2013·JAMA : the Journal of the American Medical Association·Anette G ZieglerGeorge S Eisenbarth
Oct 17, 2013·Diabetes Care·Bruce BuckinghamUNKNOWN Type 1 Diabetes TrialNet Study Group
Feb 20, 2014·Diabetes Care·Jay M SosenkoUNKNOWN Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups
May 9, 2014·Diabetes Care·Boris WaldmanUNKNOWN FIELD Study Investigators
Jun 11, 2014·JAMA : the Journal of the American Medical Association·Mikael KnipUNKNOWN TRIGR Study Group

❮ Previous
Next ❯

Citations

Apr 18, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Moufida Ben Nasr, Paolo Fiorina
May 22, 2016·Diabetes·Helen E ThomasThomas W H Kay
Oct 25, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jane H Buckner, Carla J Greenbaum
May 12, 2018·Diabetes, Obesity & Metabolism·Francois CurtinUNKNOWN RAINBOW-T1D investigators
Mar 22, 2019·Diabetes·Tania HabibUNKNOWN Type 1 Diabetes TrialNet Study Group
Mar 25, 2019·Current Diabetes Reports·Griselda Lim Loo XinDinesh Kumar Chellappan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Annals of the New York Academy of Sciences
Jay S SkylerType 1 Diabetes TrialNet Study Group
Seminars in Immunology
Aaron W Michels, George Eisenbarth
World Journal of Diabetes
Kimber Simmons, Aaron W Michels
© 2021 Meta ULC. All rights reserved